This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

This limited competition Funding Opportunity Announcement solicits the renewal application for the Chernobyl Tissue Bank Coordinating Center. The Chernobyl Tissue Bank is a collaborative resource that is supported by the National Cancer Institute and another international partner and includes active participation of countries critically affected by the Chernobyl nuclear power plant accident. The objective of the Chernobyl Tissue Bank is to maintain a research resource that supports current and future studies on the biology of thyroid cancer, a major health consequence of the Chernobyl accident. The Chernobyl Tissue Bank Coordinating Center is the critical infrastructure that serves this goal and functions to lead, plan, integrate, and achieve the stated research objectives in collaboration with the participating institutions in the Chernobyl-affected countries.

The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

The proposed Program may address any of the broad areas of cancer research, including (but not limited to) cancer biology, cancer prevention, cancer diagnosis, cancer treatment, and cancer control. Basic, translational, clinical, and/or population-based studies in all of these research areas are appropriate. Each application submitted in response to this FOA must consist of at least three research projects and an Administrative Core. The projects must share a common central theme, focus, and/or overall objective.

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front-yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 to researchers with a novel approach to pediatric oncology scientific investigation. That can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of having successfully competed for extramural funding.

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front-yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 to researchers with a novel approach to pediatric oncology scientific investigation. That can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of having successfully competed for extramural funding.

Rally funds research in the following areas: -Under-studied cancer types -Innovative approaches to childhood cancer research which could lead to advanced studies or clinical trials -Studies that are likely to lead to a clinical trial, personalized, alternative, or integrated research proposals -Quality of life and survivorship research proposals

The annual Pancreatic Cancer Action Network-AACR Research Career Development Awards represent a joint effort to encourage and support junior faculty who have completed their most recent doctoral degree or medical residency within the past eleven years to conduct pancreatic cancer research and establish successful career paths in the field. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer.

The purpose of the U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer program is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Russian researchers in the areas of cancer biology, prevention, early detection, diagnosis, and treatment as well as the physical and chemical sciences and engineering in cancer biology, nanotechnology, and radiation epidemiology.

The purpose of the U.S.-Russia Bilateral Collaborative Research Partnerships on Cancer program is to stimulate collaborative basic, translational, and clinical research between United States (U.S.)-based researchers and Russian researchers in the areas of cancer biology, prevention, early detection, diagnosis, and treatment as well as the physical and chemical sciences and engineering in cancer biology, nanotechnology, and radiation epidemiology.

The NCI's Diversity Training Branch (DTB) and the Center to Reduce Cancer Health Disparities (CRCHD) announce the availability of the "Mentored Patient-Oriented Research Award to Promote Diversity" for career development of individuals with a health professional doctoral degree from groups currently underrepresented on a national level in the biomedical, clinical, behavioral, and social sciences. The NCI recognizes a unique and compelling need to promote diversity in the patient-oriented research workforce.   

The purpose of the NCI Mentored Research Scientist Development Award (K01) is to enhance the diversity of the NCI-funded cancer research workforce by supporting eligible individuals from groups that have been shown to be underrepresented in the biomedical, behavioral, social and clinical sciences. This FOA provides salary and research support for a sustained period of "protected time" for intensive research career development under the guidance of an experienced mentor, or sponsor. The Diversity Training Branch (DTB) of the Center to Reduce Cancer Health Disparities (CRCHD), at the National Cancer Institute (NCI), invites career development award applications (K01) from individuals from backgrounds that have been shown to be underrepresented in health-related science.

The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

The AACR NextGen Grants for Transformative Cancer Research represent the AACR's flagship funding initiative to stimulate highly innovative research from young investigators. This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that may not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries and help talented young investigators gain scientific independence. The grants provide $450,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants, research/laboratory supplies, equipment, travel applicable to the research project, publication charges for manuscripts that pertain directly to the funded project, other research expenses, and indirect costs.

The AACR NextGen Grants for Transformative Cancer Research represent the AACR's flagship funding initiative to stimulate highly innovative research from young investigators. This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that may not be funded through conventional channels. It is expected that these grants will catalyze significant scientific discoveries and help talented young investigators gain scientific independence. The grants provide $450,000 over three years for expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants, research/laboratory supplies, equipment, travel applicable to the research project, publication charges for manuscripts that pertain directly to the funded project, other research expenses, and indirect costs.

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I- Corps™ program is being offered. The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will provide administrative supplement awards to two cohorts of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps™ at NIH Program. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

This funding opportunity announcement (FOA) seeks to develop and nurture a national innovation ecosystem that builds upon biomedical research to develop technologies, products and services that benefit society. Toward meeting this objective, the I- Corps™ program is being offered. The I-Corps™ at NIH program is focused on educating researchers and technologists on how to translate technologies from the lab into the marketplace. Under this FOA, participating NIH and CDC Institutes and Centers will provide administrative supplement awards to two cohorts of currently-funded SBIR and STTR Phase I grantees to support entrepreneurial training under the I-Corps™ at NIH Program. The program is designed to provide three-member project teams with access to instruction and mentoring in order to accelerate the translation of technologies currently being developed with NIH and CDC SBIR and STTR funding. It is anticipated that outcomes for the I-Corps™ teams participating in this program will include significantly refined commercialization plans and well-informed pivots in their overall commercialization strategies. Prospective applicants are strongly encouraged to contact NIH or CDC Scientific/Research staff for more information about the program before applying.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.  

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

The Lung Cancer Research Foundation's grant program provides funding for innovative research focused on the prevention, diagnosis, treatment and cure of lung cancer. The Foundation encourages applications for projects investigating a wide variety of research topics.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCIs Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention.

The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for research projects designed to use sound and innovative strategies to solve specific problems and paradoxes in childhood cancer research identified by the National Cancer Institute (NCI) as the NCIs Pediatric Provocative Questions (Pediatric PQs). These problems and paradoxes framed as questions are not intended to represent the full range of NCI's priorities in childhood cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of pediatric cancer research that are deemed important but have not received sufficient attention.

This Funding Opportunity Announcement (FOA) encourages transdisciplinary research that will leverage cognitive neuroscience to improve traditional measurement of cognitive impairment following cancer treatment, often referred to as chemobrain. A better understanding of the acute- and late-term cognitive changes following exposure to adjuvant chemotherapy and molecularly-targeted treatments, including hormonal therapy, for non-central nervous system tumors can inform clinical assessment protocols with downstream implications for survivorship care plans.

The purpose of this Funding Opportunity Announcement (FOA) is to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers. The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this FOA) must be focused on cancers of the breast, prostate and other genitourinary organs, and lung. In addition, cancers with rapidly rising incidence.

The PRCRP Career Development Award supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher (i.e., the Designated Mentor) as an opportunity to obtain the funding, guidance, and experience necessary for productive, independent careers at the forefront of cancer research. This award supports impactful research projects with an emphasis on discovery. Under this award mechanism, the early-career investigator is considered the Principal Investigator (PI), and the application should focus on the PI's research and career development. It should be clear that the proposed research is intellectually designed by the PI and not a product of the Designated Mentor.

The purpose of this funding opportunity is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more exploratory research. Possible topics of study include, but are not limited to, the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study design ranging from basic science animal models through small prospective randomized controlled trials. The intent of this R21 funding initiative is to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of research projects addressing these topics. These studies may incur considerable research risk in efforts to make important breakthroughs in the understanding, prevention and treatment of MODS in children. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant activity code. It is hoped that the results of this exploratory research will translate into improved clinical outcomes for children with, and at risk for MODS.